Abstract
Programmed cell death (pcd) is a form of cell death in which the cell plays an active role in its own demise. Pcd plays a critical role in the development of the nervous system, as well as in its response to insult. Both anti-pcd and pro-pcd modulators play prominent roles in development and disease, including neurodegeneration, cancer, and ischemic vascular disease, among others. Over 100,000 published studies on one form of programmed cell death — apoptosis — have appeared, but recent studies from multiple laboratories suggest the existence of non-apoptotic forms of programmed cell death, such as autophagic programmed cell death. In addition, there appear to be programmatic cell deaths that do not fit the criteria for either apoptosis or autophagic cell death, arguing that additional programs may also be available to cells. Constructing a mechanistic taxonomy of all forms of pcd — based on inhibitors, activators, and identified biochemical pathways involved in each form of pcd — should offer new insight into cell deaths associated with various disease states, and ultimately offer new therapeutic approaches.
Keywords: Programmed cell death, autophagy, caspase, apoptosis, paraptosis, dependence receptors, neurodegeneration, Alzheimer's disease
Current Molecular Medicine
Title: Programmed Cell Death Mechanisms in Neurological Disease
Volume: 8 Issue: 3
Author(s): Dale E. Bredesen
Affiliation:
Keywords: Programmed cell death, autophagy, caspase, apoptosis, paraptosis, dependence receptors, neurodegeneration, Alzheimer's disease
Abstract: Programmed cell death (pcd) is a form of cell death in which the cell plays an active role in its own demise. Pcd plays a critical role in the development of the nervous system, as well as in its response to insult. Both anti-pcd and pro-pcd modulators play prominent roles in development and disease, including neurodegeneration, cancer, and ischemic vascular disease, among others. Over 100,000 published studies on one form of programmed cell death — apoptosis — have appeared, but recent studies from multiple laboratories suggest the existence of non-apoptotic forms of programmed cell death, such as autophagic programmed cell death. In addition, there appear to be programmatic cell deaths that do not fit the criteria for either apoptosis or autophagic cell death, arguing that additional programs may also be available to cells. Constructing a mechanistic taxonomy of all forms of pcd — based on inhibitors, activators, and identified biochemical pathways involved in each form of pcd — should offer new insight into cell deaths associated with various disease states, and ultimately offer new therapeutic approaches.
Export Options
About this article
Cite this article as:
Bredesen E. Dale, Programmed Cell Death Mechanisms in Neurological Disease, Current Molecular Medicine 2008; 8 (3) . https://dx.doi.org/10.2174/156652408784221315
DOI https://dx.doi.org/10.2174/156652408784221315 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Insight Into Mitochondrial Dysfunction and its Implications in Neurological Diseases
Current Drug Targets Commentary-1 Research Highlights (Never Underestimate the Power of Adenosine in Multiple Sclerosis)
CNS & Neurological Disorders - Drug Targets Lipid Raft Alterations in Aged-Associated Neuropathologies
Current Alzheimer Research Emerging Evidence for the Role of Neurotransmitters in the Modulation of T Cell Responses to Cognate Ligands
Central Nervous System Agents in Medicinal Chemistry Anti-IL-1 β Therapies
Recent Patents on DNA & Gene Sequences Editorial (Hot Topic: Palmitoylethanolamide: Biochemistry, Pharmacology and Therapeutic Use of a Pleiotropic Anti-Inflammatory Lipid Mediator)
CNS & Neurological Disorders - Drug Targets Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Therapeutic Efficacy of Selegiline in Neurodegenerative Disorders and Neurological Diseases
Current Drug Targets Exploring the Role of Monoamine Oxidase Activity in Aging and Alzheimer’s Disease
Current Pharmaceutical Design Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry P2X7 Receptors: Channels, Pores and More
CNS & Neurological Disorders - Drug Targets Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinsons Disease
Current Neuropharmacology In the Rush for Green Gold: Can Green Tea Delay Age-Progressive Brain Neurodegeneration?
Recent Patents on CNS Drug Discovery (Discontinued) Neurovascular Matrix Metalloproteinases and the Blood-Brain Barrier
Current Pharmaceutical Design Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Gene Therapy for Peripheral Nervous System Diseases
Current Gene Therapy Heat Shock Response Regulates Insulin Sensitivity and Glucose Homeostasis: Pathophysiological Impact and Therapeutic Potential
Current Diabetes Reviews GSTP1 Polymorphisms and their Association with Glutathione Transferase and Peroxidase Activities in Patients with Motor Neuron Disease
CNS & Neurological Disorders - Drug Targets Aggresome Formation and Neurodegenerative Diseases: Therapeutic Implications
Current Medicinal Chemistry Nanotechnology and Antioxidant Therapy: An Emerging Approach for Neurodegenerative Diseases
Current Medicinal Chemistry